Product Images Alendronate Sodium

This is a graph showing the cumulative incidence of hip fractures in patients with radiographic vertebral fracture at baseline over a three-year study of FIT. The graph presents two types of patients: those who received placebo treatment and those who were treated with Alendronate Sodium. The X-axis shows the time in months and the Y-axis represents the cumulative incidence of hip fractures in percentages.*

This text seems to provide results from a study on the treatment of osteoporosis in postmenopausal women, with a focus on the increase in bone mineral density (BMD) over three years using alendronate sodium at a 10 mg/day dose. The text also lists numerical values for BMD in different areas of the body, such as the lumbar spine, femoral neck, and trochanter.*

Osteoporosis Treatment Studies in Postmenopausal women with Alendronate Sodium 10 mg/day Versus Placebo showed a time course of effect on Lumbar Spine BMD percent change from baseline in both US and multinational study groups. The mean percentage change in BMD from baseline was recorded over a course of 37-72 months.*

This is a description of a study on the impact of Alendronate Sodium 40mg/day on Paget's Disease of Bone, as compared to a placebo or Etidronate 400mg/day. The study included 27 participants and measured the effect on serum alkaline phosphatase levels over time. The results are presented in a graph showing the mean percentage change from baseline levels for each treatment group over a period of months.*